14 results about "Organ Specificity" patented technology

In accordance with the purpose(s) of the present disclosure, as embodied and broadly described herein, the disclosure, in one aspect, relates to lipid nanoparticles for use as drug delivery agents. The lipid nanoparticles are composed of lipopeptide conjugates, where a peptide is bonded to a lipid. The lipid nanoparticles described herein represent a new approach in drug delivery, addressing critical challenges in balancing biodegradability, biocompatibility, and organspecific targeting. The lipid nanoparticles can selectively target and deliver bioactive agents to specific tissues in a subject by modifying specific amino acids and ratios thereof in the peptide of the lipopeptide conjugate.

The invention relates to a preparation method and application of a metal ion type lipid nanoparticle delivery system for regulating mRNA transfection. The method comprises the following steps: (1) mixing mRNA and metal ions in a solvent for 5-15 minutes to obtain a mixture solution (water phase); and (2) blowing, beating and mixing the nanoparticle-containing solvent obtained in the step (1) and a lipid solvent, and wrapping the mixture in the water phase with lipid nanoparticles to obtain the metal ion type lipid nanoparticle delivery system for regulating mRNA transfection. The preparation method has the characteristics of mild preparation conditions and simple preparation steps. According to the application, the organ specific transfection capacity of a lipid nanoparticle delivery system containing different metal ions is verified through mouse experiments. An in-vitro imaging result shows that the system has an enhancement or inhibition effect on mRNA transfection in different organs. The discovery provides a reference basis for metal ion selection for clinically and accurately regulating mRNA in-vivo transfection, and has an important guiding value.

The present invention relates to a method for preparing organ-specific mesenchymal cells from pluripotent stem cell-derived intestinal organoid stromal cells. By using cells derived from stromal cell layers adjacent to intestinal organoids for differentiation into organ-specific mesenchymal cells, the present invention can greatly increase the efficiency of differentiation into stromal cells through the regulation of retinoic acid (RA) and hedgehog (HH) signaling pathways, and can increase the expression of organ-specific markers without exhibiting undifferentiated state cell characteristics, and thus mesenchymal cells having well-simulated biological characteristics can be prepared.

The invention relates to a drug combination data processing method and system based on organ adverse reactions, and the method comprises the steps: carrying out the graph neural network fusion of multi-source patient medical data, and carrying out the cross-scale integration of organ function parameters, metabolic characteristics and hemodynamic data; extracting a core biomarker by utilizing principal component analysis and organ specificity screening, and generating a feature vector representing organ reaction; constructing a nonlinear drug interaction model by combining a dose-time sequence and in-vitro experimental data, and quantifying the strength of synergy and antagonism; gene expression profiles, pathological states and lifestyle data are introduced for triple dynamic calibration, and individualized adverse reaction probability optimization is achieved; monte Carlo sampling is adopted to simulate an organ toxicity scene, and intelligent classification decision is performed on a high-risk combination scheme based on a supervision rule base. The method breaks through the limitation of data islands, static evaluation and individualization deficiency in the traditional technology, and significantly improves the prediction precision and clinical applicability of the drug combination safety.

Described herein are recombinant viral genomes comprising a nucleotide sequence encoding a telomerase reverse transcriptase (TERT) operably linked to a tissue-specific and / or organ-specific promoter. Aspects described herein may be used in the treatment of conditions associated with shortened telomere length, such as pulmonary fibrosis, myocardial infarction and conditions associated therewith.

A microfluidic chip may comprise a plurality of separate microfluidic regions formed into a chip substrate. Each microfluidic region may be configured to simulate an organ and may comprise at least one inlet and at least one outlet with a microfluidic channel therebetween. Connecting microfluidic pathways may be provided between the separate microfluidic regions. The connecting microfluidic pathways may be configured to be vascularized. The connecting microfluidic pathways may comprise a surface treatment configured to receive endothelial cells. The surface treatment may comprise an extracellular matrix protein coating. Endothelial cells may be disposed within the connecting microfluidic pathways. The endothelial cells may comprise organ-specific endothelial cells that match an organ simulated by at least one of the separate microfluidic regions. The connecting microfluidic pathways may comprise synthetic microvascular networks having non-linear channels with physiologically relevant geometries. The physiologically relevant geometries may comprise bifurcations, varying cross-sectional areas, and convolutions.

The invention discloses safe and efficient peptidyl ionizable lipid as well as a preparation method and application thereof. The peptidyl ionizable lipid is a compound as shown in a formula II, and n in the formula II is an integer from 1 to 7. The LNP prepared on the basis of the compound shown in the formula II achieves synergistic balance among curative effect, safety and organ specificity, serves as a next-generation liver PILOT delivery platform, and provides key support for clinical convertible mRNA therapy.

This invention belongs to the field of organoid culture technology, specifically relating to a highly efficient organoid anticontamination reagent. This highly efficient organoid anticontamination reagent is composed of Primocin, amphotericin B, and Y-27632. In the organoid culture medium system, the final concentration of Primocin is 20-70 μg / mL, the final concentration of amphotericin B is 0.1-1 μg / mL, and the final concentration of Y-27632 is 5-20 μM. The highly efficient organoid anticontamination reagent provided by this invention exhibits dual high-efficiency inhibition against both bacteria and fungi, has a broad anticontamination spectrum, and is not prone to inducing microbial resistance. Simultaneously, it can reduce cytotoxicity, and long-term use does not alter the expression of organoid-specific markers, thus maintaining differentiation function.

The invention provides a promoter pchsA derived from petunia, a gene expression cassette of betacyanin and application of the gene expression cassette, and belongs to the technical field of plant genetic engineering. The nucleotide sequence of the promoter pchsA is shown as SEQ ID No.1; according to the invention, a petunia organ specific promoter pchsA is utilized to construct a gene expression cassette of the betacyanin, so that heterologous synthesis of the betacyanin is successfully driven in tobacco, and expression and accumulation of the betacyanin in tissues of roots, stems, leaves and flowers of the tobacco are realized. According to the invention, a new transgenic tobacco germplasm capable of efficiently accumulating the betacyanin is created, a new material is provided for plant bioreactor production of the high-value pigment (betacyanin), and meanwhile, a method for rapidly, intuitively and visually detecting the activity of the promoter is established.

A microfluidic chip may comprise a plurality of separate microfluidic regions formed into a chip substrate. Each microfluidic region may be configured to simulate an organ and may comprise at least one inlet and at least one outlet with a microfluidic channel therebetween. Connecting microfluidic pathways may be provided between the separate microfluidic regions. The connecting microfluidic pathways may be configured to be vascularized. The connecting microfluidic pathways may comprise a surface treatment configured to receive endothelial cells. The surface treatment may comprise an extracellular matrix protein coating. Endothelial cells may be disposed within the connecting microfluidic pathways. The endothelial cells may comprise organ-specific endothelial cells that match an organ simulated by at least one of the separate microfluidic regions. The connecting microfluidic pathways may comprise synthetic microvascular networks having non-linear channels with physiologically relevant geometries. The physiologically relevant geometries may comprise bifurcations, varying cross-sectional areas, and convolutions.

This disclosure provides a method for alleviating aluminum toxicity in hydroponic peas based on menadione-mediated reactive oxygen species (ROS) metabolism. The core components include: regulating the concentration and duration of menadione treatment to optimize the spatiotemporal accumulation pattern of ROS (superoxide anion, hydrogen peroxide) in the roots of hydroponic peas; adjusting the dynamic response of endogenous antioxidant enzyme systems (SOD, POD, APX) to enhance menadione-mediated ROS scavenging capacity; controlling the initial ROS burst based on changes in plasma membrane NADPH oxidase (Rboh) gene expression and enzyme activity to inhibit the aluminum stress oxidative signaling cascade; and adjusting the timing and frequency of menadione administration based on subcellular-scale mitochondrial and chloroplast ROS leakage rates to alleviate organ-specific oxidative damage. This approach addresses five key issues: aluminum-induced oxidative damage, cellular redox imbalance, oxidative signaling cascade, organ-specific oxidative damage, and persistent aluminum toxicity metabolic disorders.

The invention discloses a tumor animal model construction method for simulating clinical metastasis characteristics, and relates to the technical field of biological medicine. Comprising the following steps: S1, modifying a CXCR4 chemokine receptor of a tumor cell: modifying a target tumor cell by adopting a CRISPR-Cas9 technology; high-efficiency targeting of tumor metastasis is realized through double mechanisms of CXCR4 gene precise modification and target organ microenvironment directional regulation and control: on one hand, a CRISPR-Cas9 technology is used for editing a CXCR4 gene key functional region, so that the receptor expression quantity is stably increased by 2-5 times, and the chemotactic response capability of tumor cells is enhanced; on the other hand, recombinant human SDF-1alpha is locally injected, a specific chemotactic signal gradient is constructed for a target organ, the final model can achieve the effects that the number of target organ transfer lesions is larger than or equal to 5 / organ, the non-target organ transfer rate is smaller than or equal to 10%, the clinical transfer rule is strictly followed, the clinical'primary lesion-target organ 'transfer path is accurately reengraved, and the target organ transfer rate is smaller than or equal to 10%. And the defects of random transfer and poor target organ specificity of the traditional model are thoroughly improved.

The present disclosure relates to a cell culture apparatus provided with one or more biologic scaffolds (e.g., tissue-specific, bone-specific and / or organ-specific scaffolds), a method for cell cultivation by using the cell culture apparatus, and a cell culture incubator comprising the cell culture apparatus. More specifically, the cell culture apparatus comprises a plurality of cell culture modules arranged adjacent to each other. Each cell culture module comprises two or more culture medium reservoirs connected by two or more flow channels to a top-loaded chamber. The top-loaded chamber has a porous biologic scaffold arranged therein such that the biologic scaffold is at least partly exposed to a culture medium flow passing between the culture medium reservoirs through the top-loaded chamber. The apparatus thus configured may facilitate efficient biologic scaffold-assisted cell cultivation in vitro.

The invention relates to the technical field of plant biology, in particular to an expression construct combination product and a method for producing parthenocarpic siraitia grosvenorii. The combination product comprises expression constructs a) and b), the invention relates to a floral organ specific promoter having an iaaM gene and a floral organ specific promoter operably linked to the iaaM gene; b) having an IAA9 gene and a leaf tissue specific promoter operably linked to said IAA9 gene. According to the construction body, the fruit setting rate under the non-pollination condition can be remarkably increased, the siraitia grosvenorii fruits which are complete in structure and free of seeds are formed, the artificial pollination burden and the follow-up mogroside extraction cost are reduced or eliminated, and the siraitia grosvenorii fruits with few seeds or free of seeds can be produced.